

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE

HEALTH TECHNOLOGY APPRAISAL PROGRAMME

Equality impact assessment – Scoping

STA ivabradine for the treatment of chronic heart failure

The impact on equality has been assessed during this appraisal according to the principles of the NICE Equality scheme.

1. Have any potential equality issues been identified during the scoping process (draft scope consultation and scoping workshop discussion), and, if so, what are they?

During scoping it was noted that the SHIFT trial recruited mainly white males and the proportion over the age of 65 years was low. Recruitment in the UK was low.

2. What is the preliminary view as to what extent these potential equality issues need addressing by the Committee?

It was noted that this was a general problem with regard to clinical trial recruitment. It was noted that it would only be an issue if the Committee recommended ivabradine in young white males. As the appraisal is not restricted to males, or any particular age group, this is not considered an equalities issue under the legislation for this appraisal topic.

3. Has any change to the draft scope been agreed to highlight potential equality issues?

No change to the scope was required.

4. Have any additional stakeholders related to potential equality issues

been identified during the scoping process, and, if so, have changes to the matrix been made?
None

Approved by Associate Director (name): Frances Sutcliffe

Date: 03 02 2012